Literature DB >> 18502829

Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1.

Martin Stern1, Loredana Ruggeri, Marusca Capanni, Antonella Mancusi, Andrea Velardi.   

Abstract

Inhibitory killer cell immunoglobulin receptors (KIR) bind to major histocompatibility complex antigens. Concise knowledge of KIR ligands allows prediction of natural killer (NK)-cell alloreactivity after hematopoietic stem cell transplantation. KIR3DL1 binds to the Bw4 epitope on HLA-B antigens. Although the same epitope is also found on 4 HLA-A antigens (HLA-A23/24/25/32), these are not currently regarded as KIR3DL1 ligands. We show that expression of HLA A*2301, A*2402, or A*3201 but not HLA A*2501 protects target cells from lysis by KIR3DL1(+) NK cells. KIR3DL1(+) NK cells from donors expressing the Bw4 epitope on an HLA-A antigen only are fully functional and capable of lysing Bw4(-) target cells. HLA A25 differs at amino acid 90, close to the serologic Bw4 epitope, from A23/24/32 and from Bw4(+) HLA-B antigens. These data suggest that HLA-A antigens should be taken into consideration when assessing the potential for NK alloreactivity after hematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502829     DOI: 10.1182/blood-2008-02-137521

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

2.  Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers.

Authors:  Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

Review 3.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

4.  HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors.

Authors:  Jodie P Goodridge; Aura Burian; Ni Lee; Daniel E Geraghty
Journal:  J Immunol       Date:  2013-09-09       Impact factor: 5.422

5.  KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding.

Authors:  Tiernan J Mulrooney; Aaron C Zhang; Yehuda Goldgur; Jeanette E Boudreau; Katharine C Hsu
Journal:  J Immunol       Date:  2015-06-24       Impact factor: 5.422

6.  The profile of KIR3DL1 and KIR3DS1 alleles in an African American population resembles that found in African populations.

Authors:  B Jiang; L Hou; M Chen; J Ng; C K Hurley
Journal:  Tissue Antigens       Date:  2010-03-10

7.  The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.

Authors:  Zahra Kiani; Franck P Dupuy; Julie Bruneau; Bertrand Lebouché; Christelle Retière; Daniel E Geraghty; Nicole F Bernard
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

8.  Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Authors:  Junli Yu; Jeffrey M Venstrom; Xiao-Rong Liu; James Pring; Reenat S Hasan; Richard J O'Reilly; Katharine C Hsu
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

Review 9.  Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy.

Authors:  Wayne M Yokoyama; Marcus Altfeld; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-14       Impact factor: 5.742

Review 10.  The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).

Authors:  Bree Foley; Martin Felices; Frank Cichocki; Sarah Cooley; Michael R Verneris; Jeffrey S Miller
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.